Sign in

CIK 0001035354

  • Non-accelerated filer
  • Smaller reporting company

Eloxx Pharmaceuticals, Inc.

Sign in to watch
Ticker
ELOX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
841368850
Phone
+1 781-577-5300
Business address
P.O. BOX 274, ARLINGTON, MA, 02476
Former names
Sevion Therapeutics, Inc., SENESCO TECHNOLOGIES INC, NAVA LEISURE USA INC
  1. 4 Open-market buy 10% owner bought 75,000 shares at $9.75 ($731,250)
  2. 4 Open-market buy 10% owner bought 350,000 shares at $9.75 ($3,412,500)
  3. 4 Open-market buy Director bought 350,000 shares at $9.75 ($3,412,500)
  4. 4 Open-market buy Director bought 300,000 shares at $9.75 ($2,925,000)
  5. 4 Open-market buy Director bought 350,000 shares at $9.75 ($3,412,500)
  6. 4 Open-market buy 10% owner bought 8,300 shares at an average $9.46 ($78,545)
  7. 4 Open-market buy 10% owner bought 4,500 shares at $9.64 ($43,380)
  8. 4 Open-market buy Director bought 2,000 shares at $9.49 ($18,980)
  9. 4 Open-market buy Chief Executive Officer bought 10,000 shares at $8.99 ($89,900)
  10. 4 Open-market buy Chief Financial Officer bought 4,500 shares at $8.56 ($38,520)
  11. 4 Open-market buy Director bought 12,600 shares at an average $7.76 ($97,830)
  12. 4 Open-market buy Director bought 12,600 shares at an average $7.76 ($97,830)
  13. 4 Open-market buy 10% owner bought 12,600 shares at an average $7.76 ($97,830)
  14. 4 Open-market buy Director bought 263 shares at $7.60 ($1,999)
  15. 3 Insider Initial Statement of Ownership
  16. 4/A Derivatives Options or other derivatives
  17. 4 Derivatives Options or other derivatives
  18. 3 Insider Initial Statement of Ownership
  19. 3 Insider Initial Statement of Ownership
  20. 3 Insider Initial Statement of Ownership

Page 9 of 29 · 574 filings